Core Laboratories Inc.
CLB
$10.44
-$0.16-1.51%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.98% | -25.31% | -14.38% | -36.46% | -39.97% |
| Total Depreciation and Amortization | -4.47% | -4.85% | -5.26% | -5.13% | -4.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -81.96% | -33.75% | 140.93% | 363.66% | 827.19% |
| Change in Net Operating Assets | 228.08% | 180.95% | 125.65% | 116.63% | 78.34% |
| Cash from Operations | 29.60% | 71.76% | 127.47% | 197.25% | 70.07% |
| Capital Expenditure | -23.95% | -18.66% | -23.15% | -15.40% | -33.06% |
| Sale of Property, Plant, and Equipment | 235.58% | 137.78% | 257.94% | -46.95% | -52.42% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 152.36% | 73.74% | 42.30% | 5.59% | -37.77% |
| Cash from Investing | 39.81% | 36.77% | 3.88% | -67.76% | -252.96% |
| Total Debt Issued | -58.41% | -77.60% | -78.22% | -80.92% | -42.93% |
| Total Debt Repaid | 52.03% | 62.26% | 61.14% | 66.54% | 26.37% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -346.60% | -224.45% | -140.96% | -8.76% | -13.99% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.21% | -0.37% | -0.43% | -0.48% | -0.59% |
| Other Financing Activities | 95.45% | 95.57% | 85.58% | 57.05% | 42.44% |
| Cash from Financing | 15.02% | -62.16% | -149.16% | -259.38% | -244.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 258.57% | 624.34% | 1,410.71% | 68.45% | -184.62% |